Tuberculosis, the world's most deadly infectious disease, is increasing (Note: Vitamin D fights TB)

The Quiet Resurgence of Tuberculosis

Substack - March 2026

"Only about 10 to 12 countries worldwide do not routinely administer the BCG vaccine; oddly enough, these countries have the lowest tuberculosis incidence in the world."
" In 2024 alone, an estimated 10.7 million people fell ill with TB, affecting men, women, and children across every continent."
"This biological armor is why TB requires months of combination therapy and why incomplete treatment fuels drug‑resistant strains. TB’s evolutionary strategy is simple: survive long enough to spread. And it has perfected that strategy over thousands of years."
in 2024
- Asia: 703,445 deaths
- Africa: 436,775 deaths
- South America: 21,034 deaths
- Europe: 14,724 deaths
- Oceania: 13,667 deaths
- North America: 9,155 deaths

Claude AI March 2026 Tuberculosis association with vitamin D known for 180 years

Vitamin D plays a mechanistically proven role in human defense against Mycobacterium tuberculosis, yet clinical trials of supplementation have produced frustratingly mixed results. The connection is not speculative — a 2006 landmark paper in Science demonstrated exactly how vitamin D enables macrophages to kill TB bacteria through cathelicidin production, finally explaining why sunlight and cod liver oil worked in pre-antibiotic sanatoriums. Meta-analyses consistently show that vitamin D deficiency raises TB risk 1.5- to 4.5-fold in a dose-dependent manner, and populations with the highest TB burden (India, Pakistan, Bangladesh) are precisely those with endemic vitamin D deficiency rates of 67–73%. Yet randomized controlled trials have largely failed to show that supplementation accelerates cure in drug-sensitive TB — with one striking exception: patients with multidrug-resistant TB appear to benefit enormously. The story is further complicated by rifampicin's ability to slash vitamin D levels by up to 70%, creating a vicious cycle where the disease and its treatment both deplete the very nutrient the immune system needs.

From sanatoriums to cathelicidin: 180 years of evidence

The therapeutic use of vitamin D for TB predates the identification of the vitamin itself. In 1849, C.J.B. Williams reported in the London Journal of Medicine that cod liver oil was "more beneficial... than any agent, medicinal, dietetic, or regiminal" for pulmonary tuberculosis. A re-analysis of an 1848 study found deterioration or death in 33% of standard-treatment patients versus only 19% receiving cod liver oil. By the 1860s, the sanatorium movement was flourishing — Alexander Spengler offered altitude therapies in Davos, Switzerland, and Auguste Rollier opened his Institute of Heliotherapy in Leysin in 1903, eventually operating 36 clinics where patients received graduated sunlight exposure. Rollier reported that 1,746 of 2,167 patients recovered under his care.

The most celebrated figure was Niels Finsen, who used concentrated ultraviolet light to treat lupus vulgaris (cutaneous TB) beginning in 1895. Of 804 patients treated at his institute, 83% achieved favorable outcomes — earning him the 1903 Nobel Prize in Physiology or Medicine, only the third ever awarded. Modern analysis suggests Finsen's therapy worked through photodynamic killing of porphyrins in M. tuberculosis at ~400 nm rather than direct UV germicidal action.

These therapies were displaced not because they failed, but because streptomycin (isolated in 1943) and isoniazid (introduced 1952) were faster and more convenient. By the 1950s, sanatoriums were closing. Notably, in the transitional 1940s, physicians including Dowling and Prosser Thomas cured lupus vulgaris with 100,000–150,000 IU of oral vitamin D₂ daily for 2–3 months — doses that would be considered extraordinary today.

The molecular machinery connecting vitamin D to TB killing

The mechanistic picture crystallized with the Liu et al. 2006 Science paper, which unified the historical observations into a single molecular pathway. When M. tuberculosis lipoproteins activate TLR2/1 receptors on human macrophages, two genes are simultaneously upregulated: the vitamin D receptor (VDR) and CYP27B1 (1α-hydroxylase). CYP27B1 converts circulating 25(OH)D — the inactive storage form — into 1,25(OH)₂D₃ (calcitriol) directly within the macrophage. Calcitriol then binds VDR, which heterodimerizes with retinoid X receptor and activates transcription of the antimicrobial peptide gene CAMP, encoding cathelicidin (LL-37). LL-37 is a cationic peptide that disrupts mycobacterial membranes, directly killing intracellular M. tuberculosis.

This pathway is absolutely dependent on adequate circulating 25(OH)D substrate. Liu et al. demonstrated that sera from African Americans — who have higher TB susceptibility — were inefficient at supporting cathelicidin induction due to low 25(OH)D levels. Subsequent siRNA experiments (Liu et al. 2007, J. Immunol.) confirmed that when cathelicidin is silenced, vitamin D-triggered antimicrobial activity is abolished entirely.

Beyond cathelicidin, vitamin D activates at least three additional antimycobacterial mechanisms. Autophagy — the cellular self-digestion process — is induced through a cathelicidin-dependent pathway involving Beclin-1 and ATG5, overcoming M. tuberculosis's strategy of arresting phagosomal maturation. Yuk et al. (2009, Cell Host & Microbe) showed that 1,25(OH)₂D₃ forces colocalization of mycobacterial phagosomes with autophagosomes. Fabri et al. (2011, Science Translational Medicine) demonstrated that IFN-γ from T cells requires vitamin D to execute its antimicrobial program — achieving an 85% reduction in TB colony-forming units in vitamin D-sufficient conditions, but failing entirely in deficient serum. Vitamin D also induces β-defensin 2, generates reactive oxygen species via PI3K and NADPH oxidase, and suppresses matrix metalloproteinases linked to pulmonary cavitation.

Vitamin D's relationship with adaptive immunity is nuanced. It enhances innate killing while simultaneously restraining excessive Th1 and Th17 inflammation, promoting regulatory T cells, and inhibiting dendritic cell maturation. This apparent paradox resolves because IL-12, present during active TB, partially counteracts vitamin D's Th1 suppression. The net effect is fine-tuned: enhanced bacterial killing with reduced tissue destruction.

Genetic variants in the VDR gene alter TB susceptibility

The VDR gene on chromosome 12q13.11 harbors over 63 known polymorphisms, four of which have been extensively studied in TB: FokI (rs2228570), BsmI (rs1544410), TaqI (rs731236), and ApaI (rs7975232). FokI is functionally the most important because it is the only VDR polymorphism that alters the protein's amino acid sequence. The f allele produces a longer 427-amino-acid VDR that is less transcriptionally active than the 424-amino-acid F-variant, with ~1.7-fold lower transcriptional activity in transfection studies.

Meta-analyses reveal strongly population-dependent effects. A 2024 Frontiers in Genetics meta-analysis found the FokI f allele increased TB risk overall (OR = 1.24, 95% CI: 1.04–1.48), but the signal was driven almost entirely by Han Chinese and East Asian populations, where the ff genotype conferred risks of OR = 1.97 (95% CI: 1.32–2.93) in the Huang et al. 2013 analysis. In European populations, the BsmI bb genotype was protective (OR = 0.41, 95% CI: 0.22–0.76). In African populations, the ApaI aa genotype was protective (OR = 0.66, 95% CI: 0.51–0.85). No significant VDR-TB associations have been consistently found in South Asian or American populations.

Beyond VDR, polymorphisms in the vitamin D-binding protein gene (GC) show TB associations dependent on vitamin D status. The CYP27B1 gene (rs118204012 AA genotype) has been linked to both vitamin D insufficiency and TB susceptibility in South Indian populations. These findings reinforce that genetic variation across the entire vitamin D pathway — not just the receptor — shapes TB risk.

Deficiency precedes disease in a dose-dependent gradient

The epidemiological evidence for vitamin D deficiency as a TB risk factor is substantial and includes prospective data establishing temporal precedence. A pooled individual-participant-data meta-analysis (Ganmaa et al. 2019, PLOS Medicine; 3,544 participants from 8 studies) found that vitamin D deficiency increased TB risk by 48% (aOR = 1.48, 95% CI: 1.04–2.10), with a clear dose-response: severe deficiency (<25 nmol/L) carried a 2-fold risk (aOR = 2.05, p-trend = 0.02). Among HIV-positive individuals, deficiency conferred a 2.2-fold risk (aOR = 2.18, 95% CI: 1.22–3.90).

The dose-response gradient is steep at the lowest levels. Deng et al. (2015) found that 25(OH)D ≤12.5 nmol/L carried an OR of 4.56 (95% CI: 2.20–9.44) compared to sufficient levels, while 13–25 nmol/L carried an OR of 3.80. A Pakistani household-contact cohort (Talat et al. 2010) followed 100 disease-free contacts for four years: 23% in the lowest vitamin D tertile (<7 ng/mL) progressed to active TB versus 0% in the highest tertile (adjusted RR = 5.1 per log-decrement in vitamin D).

Seasonal data provides elegant supporting evidence. In Cape Town, mean 25(OH)D peaked in summer at 56.8 nmol/L and fell to 30.7 nmol/L in winter, while TB notifications showed the exact inverse pattern (Martineau et al. 2011, PNAS). In Lima, Peru, midwinter vitamin D deficiency peaks preceded late-winter tuberculin skin test positivity peaks by 6 weeks, which in turn preceded symptom-onset peaks by 12 weeks — matching TB's expected 5-month incubation period. Remarkably, in London, TB patients lost the normal seasonal vitamin D rise seen in healthy contacts despite identical sun exposure and diet, suggesting abnormal vitamin D handling during disease.

Clinical trials show limited overall benefit but dramatic signals in subgroups

Despite compelling mechanistic and epidemiological evidence, randomized controlled trials of vitamin D supplementation have been largely disappointing for drug-sensitive TB. The most authoritative assessment — Jolliffe et al.'s 2019 individual-participant-data meta-analysis of 8 RCTs (n=1,850) in the European Respiratory Journal — found no effect on sputum culture conversion overall (aHR = 1.06, 95% CI: 0.91–1.23). The 2016 Cochrane Review concluded that "statistically significant benefits on sputum conversion have not been demonstrated."

However, three subgroup findings stand out:

Multidrug-resistant TB: Jolliffe et al. found vitamin D accelerated sputum culture conversion with an extraordinary aHR of 13.44 (95% CI: 2.96–60.90; p=0.02), though based on only ~55 patients.
VDR genotype-dependent response: Martineau et al. (2011, Lancet) found patients with the TaqI tt genotype showed an 8-fold acceleration in culture conversion (HR = 8.09, 95% CI: 1.39–47.09).
Profoundly deficient patients given daily doses: The Mily et al. 2015 Bangladesh trial, enrolling patients with baseline 25(OH)D of just 27 nmol/L and using 5,000 IU daily, showed significant culture conversion improvement (OR = 2.85, 95% CI: 1.09–7.43). A 2024 meta-analysis (Meng et al.) confirmed that daily dosing — not intermittent boluses — was associated with higher sputum smear conversion at 6 weeks (RR = 1.23, 95% CI: 1.07–1.41).

Trials showing null results generally used intermittent bolus dosing, enrolled populations that were not severely deficient, or used insufficient total doses. For TB prevention, even the largest trial — Ganmaa et al. 2020 (NEJM), with 8,851 vitamin D-deficient Mongolian schoolchildren supplemented for 3 years — found no reduction in TB infection or disease.

On dosing, tested regimens have ranged from 2.5 mg total (Ralph 2013) to 30 mg (Salahuddin 2013). No TB-specific target 25(OH)D level has been established, though ≥75 nmol/L (30 ng/mL) is the threshold used in most analyses. Safety has been consistently excellent even at high doses, with the caveat that TB's granulomatous physiology creates theoretical hypercalcemia risk from unregulated macrophage production of active vitamin D. No major guideline body — including WHO, NICE, or Cochrane — currently recommends routine high-dose vitamin D supplementation for TB, though WHO endorses supplementation "within the context of rigorous research."

The vicious cycle: TB depletes vitamin D while treatment makes it worse

Active TB depletes vitamin D through at least five mechanisms. Activated macrophages upregulate CYP27B1 in an unregulated fashion (unlike renal CYP27B1, macrophage CYP27B1 is not subject to PTH/calcium feedback), consuming circulating 25(OH)D substrate. Macrophages also express a truncated, dominant-negative form of CYP24A1 that prevents local catabolism of the active form, sustaining consumption of the 25(OH)D pool. The acute phase response independently lowers measured 25(OH)D, as vitamin D behaves as a negative acute phase reactant. Malnutrition and reduced sun exposure during illness compound the deficit.

Evidence for this depletion is robust: a meta-analysis found vitamin D deficiency was 3.23 times more prevalent in TB patients than controls (OR = 3.23, 95% CI: 1.91–5.45). Critically, some patients have persistently low 25(OH)D even years after successful treatment — a Pakistani study found recovered patients (2–10 years post-treatment) still had median 25(OH)D of just 5.1 ng/mL versus 9.6 in controls.

Rifampicin dramatically worsens this situation. As one of the most potent known activators of the Pregnane X Receptor (PXR), rifampicin massively upregulates CYP3A4, which catalyzes 4β-hydroxylation of both 25(OH)D and 1,25(OH)₂D into inactive metabolites. A classic study found that a 2-week course of rifampicin alone reduced plasma 25(OH)D by approximately 70%. Isoniazid operates through a different mechanism — CYP450 inhibition rather than induction — reducing 1,25(OH)₂D by 47% after a single dose. When combined, their effects partially offset each other, yielding a ~34% 25(OH)D reduction at 2 weeks, but progressive decline continues over months. An Indian longitudinal study documented progressive vitamin D decline throughout standard treatment (18.1 → 17.9 → 17.5 ng/mL over 6 months, p<0.001). Most concerning, in vitro evidence shows the standard four-drug TB combination significantly inhibits vitamin D-induced cathelicidin expression in macrophages, potentially undermining the immune pathway through which vitamin D contributes to bacterial control.

Geographic overlap between vitamin D deficiency and TB is striking

The world's TB burden maps remarkably onto vitamin D deficiency prevalence. India accounts for 26% of global TB cases (~2.8 million annually) while 67% of its population is vitamin D deficient. Pakistan carries 6.3% of global TB cases with 73% vitamin D deficiency. Bangladesh bears 3.5% of TB cases with 67% deficiency. A 2023 global analysis of 7.9 million participants across 81 countries found that 47.9% of the world's population had 25(OH)D below 50 nmol/L, with lower-middle-income countries and the Eastern Mediterranean Region worst affected — the same regions bearing disproportionate TB burden.

The overlap becomes starkest in migrant populations at high latitudes. In London, Indian-born TB patients were 10 times more likely to be vitamin D deficient than white patients (adjusted OR = 10.10), while Somali-born patients were 6 times more likely (OR = 6.07). Among 210 foreign-born TB patients in London, 76% were deficient and 56% had undetectable levels. Somali immigrants in Sweden showed 73% severe vitamin D deficiency (<25 nmol/L) compared to 1% of Swedish controls. In Denmark, Somali immigrants had initial TB incidence rates of 2,000 per 100,000 — an extraordinary rate linked partly to vitamin D depletion after migration from equatorial latitudes to 55°N.

Arctic populations face a dual burden. Inuit communities in Nunavut, Canada have TB rates of 155.9 per 100,000 alongside vitamin D insufficiency rates of 79–97% depending on season. Intriguingly, Greenlandic Inuit show a U-shaped TB risk curve with greater susceptibility at both <75 nmol/L and >140 nmol/L of 25(OH)D, and may possess genetic adaptations for vitamin D scarcity that complicate standard deficiency thresholds. HIV co-infection further amplifies the convergence: in South Africa, vitamin D deficiency was associated with active TB in both HIV-negative (OR = 5.2) and HIV-positive individuals (OR = 5.6), with 97% of HIV-infected TB patients insufficient in one study.

VitaminDWiki's perspective and its limitations

The advocacy website VitaminDWiki maintains an extensive tuberculosis page referencing at least 14 meta-analyses and numerous RCTs. It claims that "vitamin D both PREVENTS and TREATS TB" and highlights the 2006 Nursyam trial's 100% cure rate with 10,000 IU daily. The site correctly notes the Jolliffe et al. finding that MDR-TB patients showed 13.4-fold faster clearance with vitamin D, and references the historical use of 100,000–150,000 IU daily in the 1940s. It tracks VDR polymorphism associations, drug interaction data, and cost comparisons between vitamin D and TB drug regimens. However, VitaminDWiki is maintained by a single individual and is not a peer-reviewed source. Its editorial framing consistently emphasizes positive findings, characterizes negative trials as using "small doses," and presents claims with greater certainty than the evidence supports. While the peer-reviewed studies it references are legitimate, its interpretation should be treated as advocacy rather than scientific consensus.

Conclusion

The TB–vitamin D relationship is mechanistically proven, epidemiologically consistent, and genetically modulated — yet clinically elusive in standard drug-sensitive TB. The key unresolved tension is between the strong biological rationale (macrophage-dependent cathelicidin production requires adequate 25(OH)D substrate) and the underwhelming RCT results in drug-sensitive disease. The most promising clinical signals emerge in MDR-TB, genetically susceptible VDR genotypes, profoundly deficient patients, and daily (not bolus) dosing regimens. The finding that standard TB drugs both deplete vitamin D and suppress vitamin D-induced cathelicidin may partly explain why supplementation fails to show benefit during conventional therapy — the drugs may be undermining the very immune pathway vitamin D supports. Correcting documented deficiency during TB treatment is safe, inexpensive, and biologically rational, even as evidence remains insufficient for formal guideline endorsement. The most urgent research priorities are adequately powered trials in MDR-TB populations, head-to-head comparisons of daily versus bolus dosing in severely deficient patients, and investigation of whether active vitamin D metabolites (calcitriol) bypass the CYP3A4-mediated depletion caused by rifampicin.

Related in VitaminDWiki (prevents, treats, as well as increasing TB drug success by 13X)

Vitamin D Receptor (more likely to fight TB if the VDR is activated)